glp-1 phentermine may help certain patients lose more weight after discontinuing GLP-1s Most typically reported semaglutide; phentermine-topiramate

Walking is great, but walking is just the start," Chandler said

Propel Clear Protein introduces a new approach to protein drinkshydrating, crisp, and clear

Osteoarthritis: weight + pain In people with obesity and knee osteoarthritis , once-weekly semaglutide 2.4 mg produced: Greater weight loss Significantly larger reductions in knee pain Improved function Obstructive sleep apnea (OSA) The SURMOUNT-OSA phase 3 trials showed that tirzepatide (Zepbound) in adults with obesity and moderate-to-severe OSA: Reduced the apneahypopnea index (AHI) Lowered body weight, hypoxic burden, hsCRP, and systolic BP Improved sleep-related patient-reported outcomes compared with placebo In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity , alongside diet and physical activity

Additionally, long-term pharmacotherapy might be necessary, as stopping medication often leads to a loss of GLP-1RA benefits, even with continued lifestyle changes (Rubino et al

Practical considerations Beyond clinical factors, consider: Location convenience: You'll visit multiple times